Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
Provided By PR Newswire
Last update: Dec 12, 2025
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease
Read more at prnewswire.com1062.19
+34.68 (+3.38%)
Find more stocks in the Stock Screener
LLY Latest News and Analysis
10 days ago - By: Chartmill
